Biora Therapeutics Inc (BIOR) Actualités

Biora Therapeutics Successfully Completes Restructuring Process

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Biora Therapeutics, a biotech company developing the first...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth

Sale process will help enable next stage of product development Secures up to $10.25 million in new financing...

Form 8-K - Current report

Form 8-K - Current report

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any...

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company...